Compare Gilead Sciences, Inc. (GILD) vs Uber Technologies Inc (UBER) Price & Performance

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Uber Technologies (UBER) is trading at $75.02, up 6.46% today, with strong technical momentum and bullish moving averages. The company shows robust revenue growth from $31.9B in 2022 to $52.0B in 2025, with net income turning positive since 2023. Recent developments include expansion into autonomous vehicle partnerships and strategic workforce adjustments in HR roles.

Uber presents a compelling growth story with improving profitability and strong analyst support (81.67% buy rating). Key risks include execution challenges in autonomous vehicle deployment and competitive pressures in key markets like India. The consensus price target of $102.88 suggests significant upside potential from current levels.